Midostaurin approved for FLT3-mutated AML
M Levis - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Midostaurin was recently approved by the US Food and Drug Administration for the
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …
Acute lymphoblastic leukemia
CH Pui, MV Relling, JR Downing - New England Journal of …, 2004 - Mass Medical Soc
Acute Lymphoblastic Leukemia | New England Journal of Medicine Skip to main content Access
provided by Charite - Universitaetsmedizin Berlin The New England Journal of Medicine …
provided by Charite - Universitaetsmedizin Berlin The New England Journal of Medicine …
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
J Cortes, AE Perl, H Döhner, H Kantarjian… - The Lancet …, 2018 - thelancet.com
Background Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)
mutations in patients with acute myeloid leukaemia are associated with early relapse and …
mutations in patients with acute myeloid leukaemia are associated with early relapse and …
circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression
YM Sun, WT Wang, ZC Zeng, TQ Chen… - Blood, The Journal …, 2019 - ashpublications.org
Internal tandem duplication (ITD) mutations within FMS-like tyrosine kinase-3 (FLT3) occur
in up to 30% of acute myeloid leukemia (AML) patients and confer a very poor prognosis …
in up to 30% of acute myeloid leukemia (AML) patients and confer a very poor prognosis …
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about
13,000 adults in the United States each year. The treatment of this disease has changed …
13,000 adults in the United States each year. The treatment of this disease has changed …
Prognostically useful gene-expression profiles in acute myeloid leukemia
PJM Valk, RGW Verhaak, MA Beijen… - … England Journal of …, 2004 - Mass Medical Soc
Background In patients with acute myeloid leukemia (AML) a combination of methods must
be used to classify the disease, make therapeutic decisions, and determine the prognosis …
be used to classify the disease, make therapeutic decisions, and determine the prognosis …
Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia
J Ma, S Zhao, X Qiao, T Knight, H Edwards, L Polin… - Clinical Cancer …, 2019 - AACR
Purpose: To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or
gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute …
gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute …
Acute lymphoblastic leukemia
CH Pui, WE Evans - New England Journal of Medicine, 1998 - Mass Medical Soc
Acute lymphoblastic leukemia (ALL) is diagnosed in 3000 to 4000 persons in the United
States each year; two thirds of them are children. 1, 2 The current rate of cure of nearly 80 …
States each year; two thirds of them are children. 1, 2 The current rate of cure of nearly 80 …
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
M Levis - Hematology 2013, the American Society of …, 2013 - ashpublications.org
Patients with acute myeloid leukemia who harbor an FMS-like tyrosine kinase 3 (FLT3)
mutation present several dilemmas for the clinician. The results of an FLT3 mutation test …
mutation present several dilemmas for the clinician. The results of an FLT3 mutation test …
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression …
RGW Verhaak, CS Goudswaard, W Van Putten, MA Bijl… - Blood, 2005 - ashpublications.org
Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities
in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically …
in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically …